Harrow Health (NASDAQ:HROW) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Share on StockTwits

Harrow Health (NASDAQ:HROW) announced its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03), Fidelity Earnings reports. Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The firm had revenue of $13.52 million for the quarter, compared to analyst estimates of $12.55 million.

Shares of NASDAQ HROW traded down $1.64 during midday trading on Thursday, reaching $4.76. 78,090 shares of the company traded hands, compared to its average volume of 253,168. Harrow Health has a 52 week low of $2.22 and a 52 week high of $8.99. The stock’s 50-day moving average is $7.66. The company has a current ratio of 3.43, a quick ratio of 3.22 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $157.36 million, a P/E ratio of 7.94 and a beta of 0.06.

In related news, Director Robert J. Kammer sold 6,500 shares of Harrow Health stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $7.91, for a total transaction of $51,415.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $5.78, for a total transaction of $57,800.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,000 shares of company stock worth $154,000. Company insiders own 12.43% of the company’s stock.

Several equities analysts have recently issued reports on HROW shares. Zacks Investment Research downgraded shares of Harrow Health from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. TheStreet upgraded shares of Harrow Health from a “d-” rating to a “c” rating in a research note on Wednesday, May 1st. Finally, ValuEngine cut shares of Harrow Health from a “hold” rating to a “sell” rating in a research note on Monday.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

See Also: Google Finance Portfolio Workaround

Earnings History for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.